Professor Declan Doogan, Chairman

Declan has 30 years experience in drug development and has worked with a number of new drug development companies. He was the Global Head of Development at Pfizer until he retired from that role in 2007. Since then Declan has been President of R&D and then CEO at Amarin. He is currently the CEO of Portage Biotech, a portfolio company developing new drugs using novel protein transporters and the Chair of Biohaven, a spin out from Yale that specialises in psychiatric diseases. He has held a number of visiting professorships at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo), where he has been involved with development of strategies to enhance efficiency of the R&D process.

Professor Nick La Thangue, Chief Executive Officer

Nick has extensive experience of cancer drug development and has founded several companies, including Prolifix and Celleron Therapeutics and more recently Oxford Cancer Biomarkers. He has extensive commercial experience in the biotechnology and pharmaceutical sectors.

He is a fellow of the Royal Society of Edinburgh, a member of the European Molecular Biology Organisation (EMBO), A Fellow of the Academy of Medical Sciences, a Fellow of the Lister Institute and Professorial Fellow at Linacre College Oxford. Nick is Chair of Cancer Biology at the University of Oxford.

Professor David Kerr CBE, Chief Medical Officer

David has an international reputation for the treatment of and research into colorectal cancer and his work has been awarded with several international prizes He is Professor of Cancer Medicine, University of Oxford, and Honorary Professor at Weill-Cornell College of Medicine, New York; 2nd Military University of Shanghai; Xiamen University, China; Seoul National University, Korea. He is a Fellow of the Royal Colleges of Physicians (London, Glasgow and Edinburgh), an Honorary Fellow of the Royal College of General Practitioners, a Founding Fellow of European Academy of Cancer Sciences, Past President of the European Society of Medical Oncology(2009-11) and Fellow of the Academy of Medical Sciences.

Sangwoo Lee – Director

Sangwoo is the Director of Korean Investment Partner’s US offices, based in Silicon Valley, with worldwide experience in development of investment portfolios. Sangwoo has 18 years industry experience, prior to this, both in corporate and new venture environments, including roles with Samsung Electronics, Dasan Networks, Neomtel and Polidigm.

Ji Woong Chun – Director

Ji Woong is a Healthcare Venture Investment Team Leader in KTB Network, and on the Board of Directors of several biotech companies. Previously, he was in Daiichi Sankyo as a Global Clinical Study Manager. He has a Masters Degree from Seoul National University, and a Pharmacy Degree from Kyung Sung University.


Professor Douglas Manion, Director

Doug has 20 years experience in drug development. He was the Senior Vice President, Head of Specialty Development and Head of Japan and China R&D at BMS until October 2016.  He had leadership roles at BMS overseeing various therapeutic areas including virology, immunoscience, neurology, cardiology, metabolic diseases, genetically-defined diseases and fibrosis since joining in 2005. From 2001 to 2005, he was Vice President of Clinical Development and Medical Affairs for HIV/AIDS at GSK. He started his career at DuPont Pharmaceuticals in 1997.  He is Board Certified in Internal Medicine and completed his Fellowship in Infectious Diseases in Ottawa Canada and a clinical and bench research fellowship at Massachusetts General Hospital and Harvard Medical School.

Dr Chris Towler

Chris Towler was educated in the life sciences, gaining a PhD in Biochemistry and undertaking a number of years of post-doctoral research in the area of onco-foetal antigens. He then spent 23
years in the Pharmaceutical Industry (Glaxo and GlaxoWellcome), 13 of which were as leader of a project management organisation within the Development Directorate, followed by a period as head of International and Manufacturing Regulatory Affairs. Chris led the development teams responsible for bringing a number of major novel therapies (including Imigran, Zofran and Relenza) to the market, served as a member of the Corporate Strategy Team and was closely involved with organisational change and post-merger integration projects.
In 2001, he joined Imperial College London to assist the new Vice Chancellor, Sir Richard Sykes, particularly in the realms of strategic planning, major project management, commercialisation of
science and communication. Chris joined Oxford University in 2008 as Director of Oxford Spinout Equity Management to create a new unit with responsibility for management of the University’s
shareholdings in its spinouts and investment of University funds in portfolio companies. During the first 6 years, this unit invested around £12M in University spinouts, returned around £40M to the University and grew the overall value of the equity portfolio significantly. Chris retired from this role in August 2015 and now holds a number of NED and Board Observer roles. Chris has experience of chairmanship or board membership of both science-based and property management companies.